Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung ...(thousands of laser drilled holes. Compar...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
Date:9/14/2009
thousands of laser drilled holes. Compared to other nebulization technologies, eFlow Technology produces aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of the hand), light weight, and battery use, products incorporating eFlow Technology reduce the burden of taking daily, inhaled treatments. The eFlow Nebulizer System and eFlow Technology are proprietary to PARI Pharma and can be optimized to specific drug formulations.
About Transave, Inc.
Transave, Inc., is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of chronic lung diseases. The company's major focus is on developing antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases. The Transave team is dedicated to leveraging its development and commercialization expertise, along with its intellectual property, to bring life-extending and life-enhancing medicines to patients. For more information about Transave's technology and development programs, visit http://www.transaveinc.com/.
'/>"/>
| SOURCE Transave, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related medicine technology :
1. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
2. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
3. Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV
4. Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes
5. ISTA Pharmaceuticals Announces Preliminary Results of T-Pred Studies
6. BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
7. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
8. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
9. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
10. Vion Pharmaceuticals Announces Results of the Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
11. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
Post Your Comments:
(Date:11/20/2009)..., , PLYMOUTH MEETING, Pa., Nov. 20 /PRNew...York Times article that questions why currently a... some cancers are being ignored, ECRI Institute, a...a roadmap to the evidence on Finasteride for Prev..., The November 13, 2009, New York Times articl...
(Date:11/19/2009)..., , ARDEE, Ireland, Nov. 19 ...ced the pricing of its previously announced second...at a price to the public of $22.25 per share. The...h Bain Capital Partners, DLJ Merchant Banking, J.P...omas H. Lee Partners, L.P., certain other institut...
(Date:11/19/2009)..., , TAINAN, Taiwan, Nov. 19 /PRNewswir...f active pharmaceutical ingredients (APIs), announ...nt Compound Safety Certification from,SafeBridge(R...noPharm,s,competency and proficiency in the safe h...s (APIs), and applies to specific laboratories and...
Breaking Medicine Technology:ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Tampa Bay Radiation Oncology Announces New Full Service Center at Bruce B Downs 53170 1NIST scientists study how to stack the deck for organic solar power 13266 1NIST scientists study how to stack the deck for organic solar power 13266 2C O R R E C T I O N Osteotech Inc 53169 1C O R R E C T I O N Osteotech Inc 53169 2C O R R E C T I O N Osteotech Inc 53169 3C O R R E C T I O N Osteotech Inc 53169 4C O R R E C T I O N Osteotech Inc 53169 5C O R R E C T I O N Osteotech Inc 53169 6C O R R E C T I O N Osteotech Inc 53169 7C O R R E C T I O N Osteotech Inc 53169 8C O R R E C T I O N Osteotech Inc 53169 9...mpany,(NYSE: LLY ) announced today that the U.S. ...mbalta(R) (duloxetine HCl) for the maintenance,tre...s., "Relapse, the re-emergence of depressive symp...s a significant clinical concern," says Doug,Willi...or Eli Lilly and,Company. "This approval from the ...
...uncil,joins organizations and individuals across t...0th annual World AIDS Day, December 1, 2007. Since...unities to raise awareness,about the HIV/AIDS pand...l,and local efforts to stop AIDS., The 2007 and 2...27,years since it was first identified, the HIV/AI...
Other Medicine Technology:FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder 2FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder 3FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder 4AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic 2(Date:11/20/2009)...otentially adding to preemie delivery rate, expert...s) -- Recent reports show that the rate of preterm...s. Now, a new study suggests one reason why: Many...term birth in the first place. , About one-quar...d a baby born at 34 to 36 weeks of gestation to be...
(Date:11/20/2009)...n with seasonal flu , , FRIDAY, Nov. 20...rting that children with asthma are more likely to...u. , "Asthma has been identified as a significa...fluenza, present in 21 percent to 30 percent in th...w researchers from the Hospital for Sick Children ...
(Date:11/20/2009)...warns against the new breast cancer recommendation...Force. These guidelines may be cost-effective, but... wrong to be safe than sorry? , ...ce recommendations, published in the current issue... firestorm in the medical community. Major medical...
(Date:11/20/2009)...wswire/ -- Missouri state employees in the Southwe...e the option to choose Mercy Health Plans thanks t...nsolidated Health Care Plan (MCHCP) and Mercy Heal...ssouri regions include the following counties: Bar...s, Greene, Hickory, Howell, Jasper, Laclede, Lawre...
(Date:11/20/2009)...0 California minority advocacy gro...he Wall/Las Memorias, Latina Breast Cancer Agency,... Real Medicine Foundation today sent a letter to B... reconsider harmful and discriminatory coverage po...ly calls for an end to the practice of step therap...
Breaking Medicine News(10 mins):Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 2Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 3Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 4[0] Many Women Miscalculate Time to Full-Term Birth[0] Swine Flu May Hit Kids With Asthma Harder[1] New Breast Cancer Recommendation May Cost Lives While Saving Money [0] Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option[0] California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication
...earchers in the US felt that artistic skill is oft...nown how the brain influences artistic creativity....oke, dementia, or trauma// - would destroy your ab...visual art, fared when they suffered some kind of ...
...ording to pshycologists, believing that one can c...ur heart and circulation.// Exposure to a stressfu...use it increases blood pressure and resistance to ...moderated by many psychological factors, such as p...
...roup scientists have recently helped the Communica...re strain of cholera, which wreaked havoc in coast...athogen, transmitted through sea food, has become ...ns made the discovery. “We received calls from the...
...rological diseases seen in people who were student...y to develop. Amyotropic lateral sclerosis (ALS)//...tion. It's sometimes known as Lou Gehrig's disease...ng ALS, as well as motor neurone disease, which is...
...ording to a notice distributed by the agency, the ... United Therapeutics Corp.'s pulmonary arterial hy.... A spokesperson for the FDA told Reuters Health t...ting clearance based on an effect// on a surrogate...
...ording to new study some light was thrown on the v...ted by the condition. The study focuses on the ris.../ At least 2 percent of the population is born wit...hat eye. Some, but not all, countries place high i...
Other Medicine News:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |